title: Heterogeneity of the inhibitory effects of IL-4 in two novel B lineage acute lymphoblastic leukemia cell lines.
abstract: The present study describes two novel cell lines, DUNATIS and SILVANUS, established from B lineage acute lymphoblastic leukemia patients. Respectively, DUNATIS and SILVANUS display an early pre-B cell and a pre-B cell phenotype. Spontaneous DNA replication of both cell lines was strongly inhibited by IL-4. This effect was directly mediated by IL-4 and exerted through the CD124 IL-4 receptor chain. Notably, IL-4 was associated with rapid cell death and reduction of cellularity in DUNATIS, whereas these parameters were considerably less pronounced and only observed after longer-term exposure of the SILVANUS cells to IL-4. In addition to these differences, although both cell lines expressed FES oncoprotein, a 100 kDa protein associated with FES was strikingly found to be tyrosine-phosphorylated in response to IL-4 exclusively in DUNATIS cells. These data demonstrate that IL-4 displays heterogenous effects on leukemic B cell precursors responsive to inhibition of DNA synthesis via IL-4 mediated engagement of the CD124 receptor chain. The present findings may be of use for appreciation of the effects of IL-4 in B lineage ALL, and the novel cell lines could represent a model for further identification of target molecules in IL-4 signalling.
authors.affiliation: Schering-Plough, Laboratory for Immunological Research, Dardilly, France.
authors.forename: N
authors.initials: N
authors.lastname: Renard
authors.forename: N
authors.initials: N
authors.lastname: Harada
authors.forename: E
authors.initials: E
authors.lastname: Callet-Bauchu
authors.forename: A
authors.initials: A
authors.lastname: Miyajima
authors.forename: V
authors.initials: V
authors.lastname: Duvert
authors.forename: J
authors.initials: J
authors.lastname: Banchereau
authors.forename: S
authors.initials: S
authors.lastname: Saeland
mesh_terms: D000328:Adult; D000368:Aged; D002051:Burkitt Lymphoma / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology*; D002455:Cell Division / Q000187:drug effects; D002470:Cell Survival / Q000187:drug effects; D004261:DNA Replication / Q000187:drug effects; D004273:DNA, Neoplasm / Q000096:biosynthesis / Q000187:drug effects; D005260:Female; D006801:Humans; D015847:Interleukin-4 / Q000494:pharmacology*; D008297:Male; D009363:Neoplasm Proteins / Q000378:metabolism; D010641:Phenotype; D010766:Phosphorylation / Q000187:drug effects; D015452:Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology*; D011505:Protein-Tyrosine Kinases; D011518:Proto-Oncogene Proteins / Q000378:metabolism; D051578:Proto-Oncogene Proteins c-fes; D014407:Tumor Cells, Cultured / Q000187:drug effects
chemical_list: D004273:DNA, Neoplasm; D009363:Neoplasm Proteins; D011518:Proto-Oncogene Proteins; D015847:Interleukin-4; D011505:Protein-Tyrosine Kinases; C496645:FES protein, human; D051578:Proto-Oncogene Proteins c-fes